MET Inhibition Enhances PARP Inhibitor Efficacy in Castration-Resistant Prostate Cancer by Suppressing the ATM/ATR and PI3K/AKT Pathways

Researchers demonstrated that mesenchymal–epithelial transition (MET) inhibition enhanced sensitivity of CRPC to poly adenosine diphosphate–ribose polymerase (PARP) inhibitors by suppressing the ATM/ATR and phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathways.